The correlation between p53 mutation status and sensitivity to anti-cancer drugs has been largely investigated, revealing a more frequent occurrence of resistance to cisplatin or carboplatin chemotherapy in patients with p53 mutations than in those with wild-type p53 [14]. The gene discussed is TP53; the disease is cancer.